



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Saxagliptin + metformin](#) > [Printer-friendly PDF](#)

Saxagliptin + metformin

Trade Name:

Komboglyze

Manufacturer/Distributor:

Bristol-Myers Squibb Canada
www.bmscanada.ca

Classification:

Oral antihyperglycemic agent
DPP-4 inhibitor
Incretin enhancer

ATC Class:

A10BD10 - metformin and saxagliptin

Status:

active

Notice of Compliance (yyyy/mm/dd):

2012/07/09

Date Marketed in Canada (yyyy/mm/dd):

2013/04/25

Presentation:

Tablet: 2.5 mg saxagliptin + 500 mg metformin. DIN: 02389169
Tablet: 2.5 mg saxagliptin + 850 mg metformin. DIN: 02389177
Tablet: 2.5 mg saxagliptin + 1000 mg metformin. DIN: 02389185

Comments:

For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with saxagliptin and metformin or who are inadequately controlled on metformin alone. It is also indicated for use in combination with premixed or long/intermediate acting insulin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with saxagliptin, metformin and premixed or long/intermediate acting insulin or who are inadequately controlled on metformin and premixed or long/intermediate acting insulin alone.

Keywords: saxagliptin
metformin
diabetes

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

Search Terms:

Apply

[A](#) (37) | [B](#) (20) | [C](#) (24) | [D](#) (37) | [E](#) (40) | [F](#) (12) | [G](#) (11) | [H](#) (9) | [I](#) (24) | [K](#) (1) | [L](#) (26) | [M](#) (12) | [N](#) (7) | [O](#) (12) | [P](#) (28) | [R](#) (14) | [S](#) (27) | [T](#) (33) | [U](#) (4) | [V](#) (13) | [W](#) (2) | [Z](#) (4)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
Abatacept	Orencia	Co-stimulation modulator for rheumatoid arthritis	2006/09
Abemaciclib	Verzenio	Protein kinase inhibitor	2019/07/03
Abiraterone	Zytiga	Androgen biosynthesis inhibitor	2011/08/08
Acamprosate	Campral	Alcohol abstinence aid	2007/03
Acidinium + formoterol	Duaklir Genuair	Bronchodilator combination - LAMA plus LABA	2015/07/09
Acidinium bromide	Tudorza Genuair	Bronchodilator	2013-09
Adapalene + benzoyl peroxide	Tactuo	Acne therapy	2011/04
Adefovir dipivoxil	Hepsera	Antiviral agent	2006/10
Afatinib	Giotrif	Protein kinase inhibitor	2014/05/28
Albiglutide	Eperzan	Antihyperglycemic agent	2016/02/19
Alendronate	Fosamax	Bone resorption inhibitor	2011/03
Alglucosidase alfa	Myozyme	Enzyme replacement therapy	2007/04
Aliskiren and hydrochlorothiazide	Rasilez HCT	Renin inhibitor and diuretic	2009/09
Alitretinoin	Toctino	Immunomodulator, antiinflammatory agent	2010/10/19
Alogliptin	Nesina	Oral antihyperglycemic agent	2014/10/08

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Alogliptin + metformin</u>	Kazano	Oral antihyperglycemic agent	2014/10/08
<u>Alpelisib</u>	Piqray	Antineoplastic agent	2020/03/11
<u>Aluminum chloride hexahydrate</u>	Hydrosal gel	Antiperspirant	
<u>Aminophylline</u>	Phyllocontin	Bronchodilator	2010
<u>Apalutamide</u>	Erleada	Anti-androgen	2018/07/27
<u>Apixaban</u>	Eliquis	Anticoagulant	2012/03
<u>Apomorphine</u>	Movapo	Nonergot-derivative dopamine receptor agonist	2018/04/xx
<u>Apomorphine</u>	Kynmobi	Nonergot-derivative dopamine receptor agonist	2020/06/12
<u>Apremilast</u>	Otezla	Immunosuppressant agent	2014/12/08
<u>Aripiprazole</u>	Abilify	Antipsychotic agent	2009/07/03
<u>ASA + Meprobamate + Codeine + Caffeine</u>	282 MEP	Narcotic analgesic	
<u>Asenapine</u>	Saphris	Atypical antipsychotic	2012/03/16
<u>Asunaprevir</u>	Sunvepra	Antiviral agent	2016/04/22
<u>Avelumab</u>	Bavencio	Antineoplastic agent	2017/12/18
<u>Axicabtagene ciloleucel</u>	Yescarta	Antineoplastic agent	2019/11/27
<u>Axitinib</u>	Inlyta	Anti-tumor agent	2012/09
<u>Azacitidine</u>	Vidaza	Antineoplastic agent	2009/12/07
<u>Azelastine + fluticasone</u>	Dymista	Antihistamine and corticosteroid agent	2015/10/22
<u>Azilsartan</u>	Edarbi	Antihypertensive agent	2013/03/27
<u>Azilsartan + chlorthalidone</u>	Edarbyclor	Antihypertensive agent	2013/03/27
<u>Azithromycin dihydrate</u>	Zmax SR	Antibiotic	2010/10/29

1 [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ? [next](#) ? [last](#) »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh

U?xwumixw (Squamish Nation), and s?l?ilw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-08-14 23:18): <http://www.dpic.org/druglisting/saxagliptin-metformin>